124 related articles for article (PubMed ID: 17567729)
1. Decrease in plasma concentrations of antiangiogenic agent TSU-68 ((Z)-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid) during oral administration twice a day to rats.
Kitamura R; Yamamoto Y; Nagayama S; Otagiri M
Drug Metab Dispos; 2007 Sep; 35(9):1611-6. PubMed ID: 17567729
[TBL] [Abstract][Full Text] [Related]
2. Identification of human liver cytochrome P450 isoforms involved in autoinduced metabolism of the antiangiogenic agent (Z)-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid (TSU-68).
Kitamura R; Asanoma H; Nagayama S; Otagiri M
Drug Metab Dispos; 2008 Jun; 36(6):1003-9. PubMed ID: 18322074
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors.
Ueda Y; Shimoyama T; Murakami H; Yamamoto N; Yamada Y; Arioka H; Tamura T
Cancer Chemother Pharmacol; 2011 May; 67(5):1101-9. PubMed ID: 20676675
[TBL] [Abstract][Full Text] [Related]
4. Time-dependent induction of rat hepatic CYP1A1 and CYP1A2 expression after single-dose administration of the anti-angiogenic agent TSU-68.
Kitamura R; Matsuoka K; Nagayama S; Otagiri M
Drug Metab Pharmacokinet; 2008; 23(6):421-7. PubMed ID: 19122336
[TBL] [Abstract][Full Text] [Related]
5. Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors.
Murakami H; Ueda Y; Shimoyama T; Yamamoto N; Yamada Y; Arioka H; Tamura T
Cancer Chemother Pharmacol; 2011 May; 67(5):1119-28. PubMed ID: 20676674
[TBL] [Abstract][Full Text] [Related]
6. Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma.
Ikeda M; Shiina S; Nakachi K; Mitsunaga S; Shimizu S; Kojima Y; Ueno H; Morizane C; Kondo S; Sakamoto Y; Asaoka Y; Tateishi R; Koike K; Arioka H; Okusaka T
Invest New Drugs; 2014 Oct; 32(5):928-36. PubMed ID: 24829073
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and disposition of the novel dopamine agonist Z-7760 in rat after intravenous and oral administration.
Bollard M; Caldwell J; Taylor GW; Strolin-Benedetti M; Semeraro C
Xenobiotica; 2000 Oct; 30(10):983-91. PubMed ID: 11315106
[TBL] [Abstract][Full Text] [Related]
8. Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer.
Yoo C; Kim SB; Ro J; Im SA; Im YH; Kim JH; Ahn JH; Jung KH; Song HS; Kang SY; Park HS; Chung HC
Cancer Res Treat; 2016 Apr; 48(2):499-507. PubMed ID: 26194374
[TBL] [Abstract][Full Text] [Related]
9. Augmentation of chemotherapeutic infusion effect by TSU-68, an oral targeted antiangiogenic agent, in a rabbit VX2 liver tumor model.
Kim HC; Chung JW; Choi SH; Im SA; Yamasaki Y; Jun S; Jae HJ; Park JH
Cardiovasc Intervent Radiol; 2012 Feb; 35(1):168-75. PubMed ID: 21184227
[TBL] [Abstract][Full Text] [Related]
10. Absorption, distribution, metabolism, and excretion of CKD-732, a novel antiangiogenic fumagillin derivative, in rats, mice, and dogs.
Lee HS; Choi WK; Son HJ; Lee SS; Kim JK; Ahn SK; Hong CI; Min HK; Kim M; Myung SW
Arch Pharm Res; 2004 Feb; 27(2):265-72. PubMed ID: 15029870
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, protein binding and metabolic profile of 3H-icometasone enbutate following intravenous, oral and intratracheal administrations to Sprague-Dawley rats.
Duchêne P; Giudicelli MD; Neau B; Gronfier A; Firmin Y; Villax P; Saivin S; Houin G
Arzneimittelforschung; 1998 Apr; 48(4):371-8. PubMed ID: 9608879
[TBL] [Abstract][Full Text] [Related]
12. TSU68 prevents liver metastasis of colon cancer xenografts by modulating the premetastatic niche.
Yamamoto M; Kikuchi H; Ohta M; Kawabata T; Hiramatsu Y; Kondo K; Baba M; Kamiya K; Tanaka T; Kitagawa M; Konno H
Cancer Res; 2008 Dec; 68(23):9754-62. PubMed ID: 19047154
[TBL] [Abstract][Full Text] [Related]
13. TSU-68 (SU6668) inhibits local tumor growth and liver metastasis of human colon cancer xenografts via anti-angiogenesis.
Yorozuya K; Kubota T; Watanabe M; Hasegawa H; Ozawa S; Kitajima M; Chikahisa LM; Yamada Y
Oncol Rep; 2005 Sep; 14(3):677-82. PubMed ID: 16077974
[TBL] [Abstract][Full Text] [Related]
14. Relaxing Effect of TSU-68, an Antiangiogenic Agent, on Mouse Airway Smooth Muscle.
Tan H; Lei J; Xue L; Cai C; Liu QH; Shen J
Cell Physiol Biochem; 2017; 41(6):2350-2362. PubMed ID: 28478457
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105.
Mukai H; Sugimoto T; Ago M; Morino A
Arzneimittelforschung; 1999 Nov; 49(11):881-90. PubMed ID: 10604039
[TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetics of nitrendipine. I. Absorption, plasma concentrations, and excretion after single administration of [14C]nitrendipine to rats and dogs.
Krause HP; Ahr HJ; Beermann D; Siefert HM; Suwelack D; Weber H
Arzneimittelforschung; 1988 Nov; 38(11):1593-9. PubMed ID: 3214442
[TBL] [Abstract][Full Text] [Related]
17. Absorption, plasma concentration, and excretion after single administration of 14C-(+-)-3-(benzylmethylamino)-2,2-dimethylpropyl methyl 4-(2-fluoro-5- nitrophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate hydrochloride in rats and dogs.
Matsunaga T; Tanabe H; Mochizuki T; Okabe K; Arizono H; Taneda M; Sato H; Ishii S; Sato J; Kiyoki M
Arzneimittelforschung; 1992 Apr; 42(4):519-25. PubMed ID: 1642676
[TBL] [Abstract][Full Text] [Related]
18. The disposition of radioactivity after administration of the anthelminthic methyl-14C-5-cyclopropylcarbonyl-2-benzimidazole carbamate (ciclobendazole) to rats and dogs.
Brodie RR; Mayo BC; Chasseaud LF; Hawkins DR
Arzneimittelforschung; 1977; 27(3):593-8. PubMed ID: 577426
[TBL] [Abstract][Full Text] [Related]
19. Preclinical pharmacology and pharmacokinetics of the anti-hepatitis virus agent 2'-fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil in mice and rats.
Kong XB; Vidal P; Tong WP; Chiang J; Gloff CA; Chou TC
Antimicrob Agents Chemother; 1992 Jul; 36(7):1472-7. PubMed ID: 1510443
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of a novel antiangiogenic agent KR-31831 in rats.
Kim SJ; Lee HI; Ji HY; Moon Y; Paek IB; Lee S; Yi KY; Yoo SD; Lee HS
Biopharm Drug Dispos; 2005 Jan; 26(1):21-6. PubMed ID: 15578734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
